SEC Tracker
Get the app

Fate Therapeutics FATE

Fate Therapeutics: Ownership stake disclosure (amended)

Schedule 13D/A on Fate Therapeutics (FATE), filed with the SEC on Nov 9, 2026, 7:08 pm ET. Source: the filing on SEC EDGAR.

Ownership stake disclosure by Redmile Group, LLC (amended)

Form
Schedule 13D/A
Filed
Importance
Notable
  1. Amendment No. 11 to Schedule 13D filed on Nov 9, 2026
  2. Redmile Capital Offshore II Master Fund, Ltd. added as Reporting Person
  3. Ownership of 6,756,561 shares held by RedCo II Offshore SPV LLC

Written from the Schedule 13D/A on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Fate Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.